Stockreport

Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference [Y...

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF Benitec Biopharma Inc. Fri, February 14, 2025 at 2:00 PM GMT+1 5 min read In This Article BNTC Benitec Biopharma Inc. -Interim clinical study updates for th [Read more]